Our Mission
Advancing Cancer Diagnostics, Improving Lives
Our Vision
From translational research to patient treatment, we envision a world where comprehensive insights enrich cancer diagnosis and offer reassurance to all patients.
News & Events
Leica Biosystems Launches Cutting-Edge Digital Pathology Software at ECP 2025, Further Enhancing Extensive Suite of Solutions
In a major leap forward to enable digital transformation of clinical diagnostics, Leica Biosystems proudly showcases its latest, trailblazing additions to the Aperio Digital Pathology portfolio
Leica Biosystems Unveils Next-Gen Pathology Portfolio at ECDP 2025
In a significant stride toward transforming the future of cancer diagnostics and research, Leica Biosystems proudly showcases its latest digital pathology
Danaher and Leica Biosystems Announce Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics
Leica Biosystems at a Glance
150+ Years of Innovation
| 2012 - Present | New Era of Science & Technology |
| 2005 - 2011 | Global Expansion Accelerates |
| 1989 - 2004 | Structuring for Comprehensive Workflow |
| 1930 - 1988 | Novel Products Drive Company Growth |
| 1900 - 1930 | Microtomy Technology Advances Amidst Wartime Realities |
| 1872 - 1899 | The Creation of the Microtome and the Early Years of R. Jung GMBH |
About Danaher
Leica Biosystems is proud to be part of Danaher. Danaher’s science and technology leadership puts Leica Biosystems’ solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.